Zymeworks pauses plans to launch one ADC into clinic in favor of another asset
Zymeworks has pumped the brakes on plans to take one of its antibody-drug conjugates into the clinic so it can prioritize another candidate.
Zymeworks has pumped the brakes on plans to take one of its antibody-drug conjugates into the clinic so it can prioritize another candidate.
